STOCK TITAN

Alterity Therapeutics Ltd - ATHE STOCK NEWS

Welcome to our dedicated news page for Alterity Therapeutics (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alterity Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alterity Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.78%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
none
Alterity Therapeutics Ltd

Nasdaq:ATHE

ATHE Rankings

ATHE Stock Data

17.90M
2.54B
1%
0.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Australia
Melbourne

About ATHE

alterity therapeutics limited researches and develops therapeutic drugs for the treatment of parkinsonian's disease and other neurodegenerative diseases in australia. the company's lead drug candidates is ath434 that has completed phase i clinical trial for the treatment of parkinson's disease. it is also developing pbt2 for used as an antimicrobial agent. the company was formerly known as prana biotechnology limited and changed its name to alterity therapeutics limited in april 2019. the company was founded in 1997 and is based in melbourne, australia.